Company Profile
Rani Therapeutics Stock Price, News & Catalysts
- Ticker:
- RANI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.85 USD (+12.65%)
Close
Last updated: September 17, 2026
96.4M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, RANI closed up 12.6% at $0.8516. No new same-company headline was identified in the current news window.
Company overview
Oral Biologics Delivery
Rani Therapeutics develops capsules that deliver biologic drugs through the intestinal wall, seeking to replace injections with oral administration.
RaniPill Platform
The RaniPill capsule protects its payload during passage through the stomach and deploys a microneedle-like mechanism in the small intestine. The platform can be adapted to peptides, proteins, and antibodies.
RT-114
RT-114 uses the RaniPill HC capsule to deliver PG-102, a GLP-1/GLP-2 dual agonist being developed for obesity. Initial Phase 1 data demonstrated systemic exposure exceeding matched subcutaneous dosing.
Metabolic-Disease Partnerships
Rani is also collaborating with external developers to apply the platform to additional obesity and metabolic-disease molecules across multiple mechanisms.
Future catalysts
- Additional Phase 1a expansion data for RT-114 by the end of 2026.
- Initiation of a repeat-dose Phase 1b study of RT-114 in obesity by the end of 2026.
- Phase 1b data for RT-114 in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Rani Therapeutics (RANI)?
Rani Therapeutics (RANI) most recently closed at 0.85 USD, a +12.65% move versus the previous session.
What is the market cap of Rani Therapeutics (RANI)?
Rani Therapeutics currently has a market capitalization of 96.4M USD on BioPharmSignal.
What does Rani Therapeutics do?
Oral Biologics Delivery Rani Therapeutics develops capsules that deliver biologic drugs through the intestinal wall, seeking to replace injections with oral administration. RaniPill Platform The RaniPill capsule protects its payload during passage through the stomach and deploys a microneedle-like mechanism in the small intestine. The platform can be...
On which exchange is RANI stock listed?
Rani Therapeutics (RANI) is associated with NASDAQ, United States, Biopharma.
What is RT-114?
Additional Phase 1a expansion data for RT-114 by the end of 2026.
Which conditions is Rani Therapeutics targeting with RT-114?
Rani Therapeutics is associated with metabolic disease, obesity based on its company overview and current catalyst commentary.
How does Rani Therapeutics describe recent progress with RT-114?
Additional Phase 1a expansion data for RT-114 by the end of 2026.
What is PG-102?
RT-114 RT-114 uses the RaniPill HC capsule to deliver PG-102, a GLP-1/GLP-2 dual agonist being developed for obesity.